PI3K

Phosphoinositide 3-kinases (PI3Ks) are lipid kinases that catalyze the phosphorylation of phosphatidylinositol 4,5-bisphosphate (PI(4,5)P₂) to generate the second messenger phosphatidylinositol (3,4,5)-trisphosphate (PI(3,4,5)P₃). The production of PI(3,4,5)P₃ facilitates the recruitment and activation of pleckstrin homology (PH) domain–containing proteins at the plasma membrane, thereby initiating downstream signaling cascades essential for cellular proliferation, survival, and migration.

PI3Ks are divided into three major classes, among which Class I PI3Ks are most prominently implicated in cancer biology. Class I enzymes comprise four distinct catalytic isoforms: PI3Kα, PI3Kβ, PI3Kδ, and PI3Kγ.

Class IA PI3Ks, the subclass most commonly associated with oncogenic signaling, function as heterodimeric lipid kinases composed of a catalytic p110 subunit (p110α, p110β, or p110δ, encoded by PIK3CA, PIK3CB, and PIK3CD, respectively) and a regulatory p85 subunit.

The PI3K signaling pathway plays a central role in diverse biological processes, including cell cycle progression, cellular growth, survival, actin cytoskeletal rearrangement, migration, and intracellular vesicular trafficking.

Frequently Asked Questions
Phosphoinositide 3-kinases (PI3Ks) are a family of lipid kinases that phosphorylate phosphatidylinositol lipids to regulate cell growth, survival, metabolism, and immune signaling. PI3K activation leads to downstream AKT and mTOR pathway signaling. Aberrant PI3K signaling is frequently observed in cancer due to PIK3CA mutations, PTEN loss, or receptor tyrosine kinase activation.
Class I PI3Ks include four catalytic isoforms: PI3Kα (PIK3CA) PI3Kβ (PIK3CB) PI3Kδ (PIK3CD) PI3Kγ (PIK3CG) PI3Kα and β are broadly expressed, while PI3Kδ and γ are enriched in leukocytes and play critical roles in immune regulation. Isoform selectivity is an important consideration in drug development due to toxicity and immune effects.
PI3K inhibitors can be classified as: Pan-PI3K inhibitors Isoform-selective inhibitors (α, β, δ, γ) Dual PI3K/mTOR inhibitors Irreversible inhibitors Selectivity influences therapeutic window and toxicity profile.
While PI3K inhibitors block upstream lipid kinase activity, mTOR inhibitors act downstream at the level of mTORC1 or mTORC2. Dual PI3K/mTOR inhibitors target both nodes of the pathway and may achieve broader pathway suppression.

Items 251-275 of 411

  • Umbralisib tosylate
    Cat. No.
    A36905

    Umbralisib tosylate

    Synonyms: TGR-1202 tosylate; RP5264 tosylate

    Umbralisib tosylate is a potent and selective dual inhibitor of PI3Kδ and casein kinase-1-ε (CK1ε), exhibiting an EC50 of 22.2 nM and 6.0 μM, respectively. This compound demonstrates significant immunomodulatory effects on T cells from chronic lymphocytic leukemia (CLL) patients. Umbralisib tosylate is primarily utilized in research focused on hematological malignancies to elucidate its therapeutic potential and mechanisms of action.

    25 mg
    $1,275.00
    50 mg
    $1,625.00
    All 3 sizes
  • Umbralisib sulfate
    Cat. No.
    A36906

    Umbralisib sulfate

    Synonyms: TGR-1202 sulfate; RP-5264 sulfate

    Umbralisib sulfate is a potent and selective dual inhibitor of PI3Kδ and casein kinase-1-ε (CK1ε), with EC50 values of 22.2 nM and 6.0 μM, respectively. This compound demonstrates notable immunomodulatory effects on T cells in chronic lymphocytic leukemia (CLL). Umbralisib sulfate is a valuable tool for research into hematological malignancies, facilitating studies on cell signaling pathways and potential therapeutic strategies.

    25 mg
    $1,275.00
    50 mg
    $1,625.00
    All 3 sizes
  • DMBP
    Cat. No.
    A39437

    DMBP

    DMBP is a VPS41 inhibitor that targets late endosomal and autophagosomal fusion with lysosomes. This compound induces methuosis and effectively inhibits autophagy in cancer cells, demonstrating significant potential in cancer research. Notably, DMBP has shown efficacy in reducing metastasis in a mouse model of metastatic melanoma, making it a valuable tool for studying melanoma progression and treatment.

    1 mg
    $200.00
    5 mg
    $615.00
    All 3 sizes
  • Dactolisib hydrochloride
    Cat. No.
    A39512

    Dactolisib hydrochloride

    Synonyms: BEZ235 hydrochloride; NVP-BEZ235 hydrochloride

    Dactolisib hydrochloride is a potent dual inhibitor of class I phosphoinositide 3-kinases (PI3K) and the mammalian target of rapamycin (mTOR), specifically targeting p110α, p110γ, p110δ, and p110β with IC50 values of 4 nM, 5 nM, 7 nM, 75 nM, and 20.7 nM, respectively. This compound effectively inhibits both mTORC1 and mTORC2, making it a valuable tool for studying the PI3K/mTOR signaling pathway. Its applications include cancer research, drug development, and exploring therapeutic strategies for various diseases associated with dysregulated PI3K/mTOR signaling.

    10 mg
    $65.00
    25 mg
    $135.00
    All 4 sizes
  • PI3Kδ/BET-IN-1
    Cat. No.
    A40402

    PI3Kδ/BET-IN-1

    PI3Kδ/BET-IN-1 is a selective inhibitor targeting both PI3Kδ and the bromodomain BRD4-BD1. With an IC50 of 112 nM for PI3Kδ and 19 nM for BRD4-BD1, this compound demonstrates potent antiproliferative effects in diffuse large B-cell lymphoma (DLBCL) cells. Its dual inhibition mechanism makes it a valuable tool for research into cancer biology and therapeutic development.

    Out of stock

    All 3 sizes
  • JRN73958
    Cat. No.
    A40811

    JRN73958

    Synonyms: Reduced scytonemin

    JRN73958 is a potent inhibitor of the PI3K/Akt, MAPK, and NF-κB signaling pathways. This compound effectively reduces LPS/IFNγ-induced activation of these pathways, making it a valuable tool for investigating their roles in cancer biology, particularly in leukemia research. Additionally, JRN73958 acts as an Nrf2/ARE activator, further expanding its utility in studies related to oxidative stress and cell survival mechanisms.

    25 mg
    $1,530.00
    50 mg
    $1,950.00
    All 3 sizes
  • ST-162
    Cat. No.
    A40845

    ST-162

    ST-162 is a dual antagonist of the MAPK and PI3K signaling pathways. It demonstrates significant antitumor activity and has been shown to enhance the efficacy of immune checkpoint inhibitors. This compound is suitable for cancer research, particularly in the study of melanoma and other malignancies.

    Out of stock

    All 3 sizes
  • PI3K/PIKK-IN-1
    Cat. No.
    A41088

    PI3K/PIKK-IN-1

    PI3K/PIKK-IN-1 is a potent inhibitor of phosphoinositide 3-kinases (PI3K) and PI3-kinase-related kinases (PIKK). This compound is utilized in the development of antibody-drug conjugates (ADCs), making it valuable for therapeutic applications. It is particularly relevant in the research of various cancers, including breast cancer, multiple myeloma, Burkitt lymphoma, diffuse large B-cell lymphoma, and non-small cell lung cancer, aiding in the exploration of targeted cancer therapies.

    Out of stock

    All 3 sizes
  • PI3Kα-IN-16
    Cat. No.
    A44243

    PI3Kα-IN-16

    PI3Kα-IN-16 is a selective PI3Kα inhibitor with an IC50 value of 4.28 μM. It effectively suppresses PI3K-mediated colorectal cancer growth and migration, demonstrating its potential as a therapeutic agent. Additionally, PI3Kα-IN-16 inhibits the Wnt signaling pathway, making it a valuable tool for research in cancer biology and signaling pathways.

    Out of stock

    All 3 sizes
  • PI3Kδ-IN-27
    Cat. No.
    A53516

    PI3Kδ-IN-27

    PI3Kδ-IN-27 is a selective inhibitor of PI3Kδ, exhibiting an IC50 value of 355.3 nM. This compound demonstrates notable antiviral activity against SARS-CoV-2, making it a valuable tool for studying viral infections, particularly COVID-19. Researchers can utilize PI3Kδ-IN-27 to explore pathways related to immune response and infection mechanisms.

    Out of stock

    All 3 sizes
  • ETP-45658
    Cat. No.
    A54588

    ETP-45658

    ETP-45658 is a potent inhibitor of the phosphoinositide 3-kinase (PI3K) family, exhibiting IC50 values of 22.0 nM for PI3Kα, 39.8 nM for PI3Kδ, 129.0 nM for PI3Kβ, and 717.3 nM for PI3Kγ. Additionally, ETP-45658 demonstrates inhibitory effects on DNA-PK (IC50 = 70.6 nM) and mTOR (IC50 = 152.0 nM). This compound is valuable for cancer research, particularly in exploring the roles of PI3K signaling pathways in tumorigenesis and treatment resistance.

    1 mg
    $40.00
    5 mg
    $95.00
    All 6 sizes
  • MEK/PI3K-IN-2
    Cat. No.
    A56875

    MEK/PI3K-IN-2

    MEK/PI3K-IN-2 is a potent inhibitor targeting both MEK and PI3K pathways, exhibiting IC50 values of 352 nM for MEK1, 107 nM for PI3Kα, and 137 nM for PI3Kδ. This compound effectively reduces levels of phosphorylated AKT and ERK1/2, demonstrating significant anti-proliferative activity against various tumor cell lines. MEK/PI3K-IN-2 is valuable for research in cancer biology and therapeutic development aimed at disrupting these critical signaling pathways.

    Out of stock

    All 3 sizes
  • MEK/PI3K-IN-1
    Cat. No.
    A56878

    MEK/PI3K-IN-1

    MEK/PI3K-IN-1 is a potent inhibitor targeting MEK and PI3K pathways, exhibiting IC50 values of 124 nM for MEK1, 130 nM for PI3Kα, and 236 nM for PI3Kδ. This compound effectively reduces levels of phosphorylated AKT (pAKT) and ERK1/2 (pERK1/2), demonstrating significant anti-proliferative effects in various tumor cell lines. MEK/PI3K-IN-1 serves as a valuable tool for research in cancer therapeutics and signaling pathway analysis.

    Out of stock

    All 3 sizes
  • LAS195319
    Cat. No.
    A60431

    LAS195319

    LAS195319 is a potent and orally active inhibitor of PI3Kδ, exhibiting an IC50 of 0.5 nM. This compound demonstrates high selectivity against a wide array of proteins, lipid kinases, and GPCRs. LAS195319 effectively inhibits the infiltration of neutrophils and eosinophils, making it a valuable tool for research into respiratory diseases, including asthma and chronic obstructive pulmonary disease (COPD).

    25 mg
    $2,160.00
    50 mg
    $2,770.00
    All 3 sizes
  • VVD-442
    Cat. No.
    A63562

    VVD-442

    VVD-442 is a selective inhibitor of PI3Kα that covalently binds to cysteine 242 within the RAS-binding domain of the PI3K p110α subunit. This binding induces conformational changes that disrupt the interaction between PI3K p110α and RAS proteins, effectively blocking RAS-mediated activation of PI3K. VVD-442 is applicable in research focusing on RAS-mutant cancers and HER2-overexpressing tumors, providing valuable insights into therapeutic strategies targeting these pathways.

    1 mg
    $415.00
    5 mg
    $1,065.00
    All 4 sizes
  • COX-2/PI3K-IN-2
    Cat. No.
    A64410

    COX-2/PI3K-IN-2

    COX-2/PI3K-IN-2 is a potent inhibitor targeting both COX-2 and PI3K pathways, exhibiting an IC50 value of 2.78 nM for PI3K and a Ki value of 3.02 nM for COX-2. This compound demonstrates significant anti-inflammatory and anti-cancer activities, making it valuable for research in oncology and inflammatory disease studies. Its dual-target mechanism provides insights into the therapeutic potential of modulating these critical pathways.

    Out of stock

    All 3 sizes
  • SH-273
    Cat. No.
    A65624

    SH-273

    SH-273 is a potent dual-function compound that acts as a selective inhibitor of PI3Kγ with an IC50 of 7 nM while also stimulating STING function with an EC50 of 100 nM. This unique profile makes SH-273 a valuable tool for investigating signaling pathways involved in pancreatic cancer. Researchers can utilize SH-273 to explore the therapeutic potential of targeting PI3Kγ and enhancing STING-mediated immune responses in cancer models.

    Out of stock

    All 3 sizes
  • Antidiabetic agent 6
    Cat. No.
    A66992

    Antidiabetic agent 6

    Antidiabetic Agent 6 is a potent antidiabetic compound that primarily targets GLUT4 by activating the PI3K/AKT signaling pathway. This mechanism enhances GLUT4 translocation, leading to improved glucose uptake and subsequently lowering blood glucose levels in Streptozotocin-induced diabetic rat models. It serves as a valuable tool for researching diabetes treatment and exploring metabolic pathways involved in glucose homeostasis.

    5 mg
    $190.00
    10 mg
    $310.00
    All 5 sizes
  • IHMT-PI3Kδ-372
    Cat. No.
    A69814

    IHMT-PI3Kδ-372

    IHMT-PI3Kδ-372 is a highly selective inhibitor of PI3Kδ, exhibiting an IC50 of 14 nM. This compound demonstrates significant selectivity over other class I PI3Ks, with 56 to 83-fold differences, as well as over various protein kinases. IHMT-PI3Kδ-372 is suitable for research applications related to chronic obstructive pulmonary disease (COPD), enabling investigations into therapeutic strategies targeting this pathway.

    1 mg
    $95.00
    2 mg
    $145.00
    All 7 sizes
  • Isopsoralidin
    Cat. No.
    A69908

    Isopsoralidin

    Isopsoralidin is a phosphatidylinositol 3-kinase (PI3K) inhibitor that demonstrates potentially hepatotoxic properties and exhibits inhibitory activity on CYP2D6. This compound plays a significant role in research focused on cell signaling pathways related to cancer and metabolic disorders. Its unique mechanism of action makes it a valuable tool for studying PI3K-related biological processes and evaluating therapeutic approaches involving PI3K modulation.

    5 mg
    $355.00
    10 mg
    $580.00
    All 2 sizes
  • ILK-IN-3
    Cat. No.
    A77620

    ILK-IN-3

    ILK-IN-3 is a potent orally active inhibitor of integrin-linked kinase (ILK), a crucial regulator of cell signaling pathways associated with tumor progression and survival. This compound enhances the anticancer efficacy of Docetaxel in orthotopic LCC6 tumor models, making it a valuable tool for research in cancer therapeutics. Its ability to modulate ILK activity positions ILK-IN-3 as a significant molecule for studying cancer biology and potential treatment strategies.

    1 mg
    $25.00
    5 mg
    $50.00
    All 6 sizes
  • ILK-IN-4
    Cat. No.
    A77631

    ILK-IN-4

    ILK-IN-4 is a selective integrin-linked kinase (ILK) inhibitor that disrupts ILK-mediated signaling pathways. It demonstrates potent anti-proliferative activity in various cancer cell lines. This compound is primarily utilized in cancer research to investigate the role of ILK in tumor progression and metastasis.

    Out of stock

    All 3 sizes
  • PKI-179
    Cat. No.
    A79698

    PKI-179

    PKI-179 is a highly effective dual inhibitor of PI3K and mTOR, exhibiting IC50 values of 8 nM, 24 nM, 74 nM, 77 nM, and 0.42 nM for PI3K-α, PI3K-β, PI3K-γ, PI3K-δ, and mTOR, respectively. It demonstrates significant activity against E545K and H1047R mutant isoforms, with IC50 values of 14 nM and 11 nM. PKI-179 is utilized in cancer research due to its proven anti-tumor efficacy in vivo, making it a valuable tool for investigating the PI3K/mTOR signaling pathway in various cancer models.

    5 mg
    $205.00
    10 mg
    $335.00
    All 5 sizes
  • PI3K/mTOR Inhibitor-4
    Cat. No.
    A79701

    PI3K/mTOR Inhibitor-4

    PI3K/mTOR Inhibitor-4 is a potent orally active pan-class I PI3K/mTOR inhibitor. It demonstrates enzymatic inhibition across PI3Kα, PI3Kγ, PI3Kδ, and mTOR with IC50 values of 0.63 nM, 22 nM, 9.2 nM, and 13.85 nM, respectively. This reagent is primarily utilized in cancer research to investigate the role of the PI3K/mTOR signaling pathway in tumorigenesis and therapeutic responses.

    2 mg
    $75.00
    5 mg
    $125.00
    All 6 sizes
  • PI3K/mTOR Inhibitor-11
    Cat. No.
    A79703

    PI3K/mTOR Inhibitor-11

    PI3K/mTOR Inhibitor-11 is a potent oral inhibitor of the PI3K/mTOR signaling pathway, exhibiting IC50 values of 3.5 nM, 4.6 nM, and 21.3 nM for PI3Kα, PI3Kδ, and mTOR, respectively. This compound effectively impairs the phosphorylation of AKT and S6 proteins, thereby modulating critical cellular processes. PI3K/mTOR Inhibitor-11 is valuable for cancer research, offering insights into therapeutic strategies targeting aberrant signaling in tumors.

    5 mg
    $445.00
    10 mg
    $715.00
    All 5 sizes

Items 251-275 of 411

Added to your cart

View Cart Checkout

    Loading...